nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0204	0.0277	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0204	0.0277	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0176	0.0239	CbGbCtD
Haloperidol—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0176	0.0239	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0171	0.0232	CbGbCtD
Haloperidol—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0171	0.0232	CbGbCtD
Haloperidol—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0169	0.023	CbGbCtD
Haloperidol—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0154	0.021	CbGbCtD
Haloperidol—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0154	0.021	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0154	0.021	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0154	0.021	CbGbCtD
Haloperidol—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0153	0.0208	CbGbCtD
Haloperidol—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0153	0.0208	CbGbCtD
Haloperidol—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0145	0.0197	CbGbCtD
Haloperidol—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0136	0.0185	CbGbCtD
Haloperidol—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0134	0.0182	CbGbCtD
Haloperidol—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0132	0.0179	CbGbCtD
Haloperidol—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0128	0.0174	CbGbCtD
Haloperidol—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0126	0.0171	CbGbCtD
Haloperidol—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0126	0.0171	CbGbCtD
Haloperidol—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0123	0.0168	CbGbCtD
Haloperidol—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0123	0.0168	CbGbCtD
Haloperidol—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.012	0.0164	CbGbCtD
Haloperidol—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0116	0.0157	CbGbCtD
Haloperidol—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0116	0.0157	CbGbCtD
Haloperidol—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0114	0.0155	CbGbCtD
Haloperidol—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0113	0.0154	CbGbCtD
Haloperidol—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0113	0.0154	CbGbCtD
Haloperidol—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.011	0.015	CbGbCtD
Haloperidol—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.011	0.015	CbGbCtD
Haloperidol—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0106	0.0145	CbGbCtD
Haloperidol—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0104	0.0141	CbGbCtD
Haloperidol—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0104	0.0141	CbGbCtD
Haloperidol—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0103	0.014	CbGbCtD
Haloperidol—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0102	0.0139	CbGbCtD
Haloperidol—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0102	0.0139	CbGbCtD
Haloperidol—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00994	0.0135	CbGbCtD
Haloperidol—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.00952	0.013	CbGbCtD
Haloperidol—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00936	0.0127	CbGbCtD
Haloperidol—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00936	0.0127	CbGbCtD
Haloperidol—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.00933	0.0127	CbGbCtD
Haloperidol—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.00933	0.0127	CbGbCtD
Haloperidol—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00895	0.0122	CbGbCtD
Haloperidol—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00884	0.012	CbGbCtD
Haloperidol—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00861	0.0117	CbGbCtD
Haloperidol—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00858	0.0117	CbGbCtD
Haloperidol—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00858	0.0117	CbGbCtD
Haloperidol—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00833	0.0113	CbGbCtD
Haloperidol—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00808	0.011	CbGbCtD
Haloperidol—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00785	0.0107	CbGbCtD
Haloperidol—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00776	0.0106	CbGbCtD
Haloperidol—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00776	0.0106	CbGbCtD
Haloperidol—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00753	0.0102	CbGbCtD
Haloperidol—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00753	0.0102	CbGbCtD
Haloperidol—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00744	0.0101	CbGbCtD
Haloperidol—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00722	0.00982	CbGbCtD
Haloperidol—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0071	0.00965	CbGbCtD
Haloperidol—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0071	0.00965	CbGbCtD
Haloperidol—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.007	0.00953	CbGbCtD
Haloperidol—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00658	0.00896	CbGbCtD
Haloperidol—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00658	0.00896	CbGbCtD
Haloperidol—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00595	0.0081	CbGbCtD
Haloperidol—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00595	0.0081	CbGbCtD
Haloperidol—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00558	0.0076	CbGbCtD
Haloperidol—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00514	0.00699	CbGbCtD
Haloperidol—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00499	0.00679	CbGbCtD
Haloperidol—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00451	0.00614	CbGbCtD
Haloperidol—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00451	0.00614	CbGbCtD
Haloperidol—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00433	0.00589	CbGbCtD
Haloperidol—H1F0—semen—acquired immunodeficiency syndrome	0.00432	0.0667	CbGeAlD
Haloperidol—GRIN2B—nerve—acquired immunodeficiency syndrome	0.00342	0.0529	CbGeAlD
Haloperidol—DRD1—nerve—acquired immunodeficiency syndrome	0.00205	0.0317	CbGeAlD
Haloperidol—DRD2—nerve—acquired immunodeficiency syndrome	0.00121	0.0187	CbGeAlD
Haloperidol—UGT1A9—digestive system—acquired immunodeficiency syndrome	0.000981	0.0152	CbGeAlD
Haloperidol—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000948	0.0146	CbGeAlD
Haloperidol—CBR1—skin of body—acquired immunodeficiency syndrome	0.000923	0.0143	CbGeAlD
Haloperidol—GRIN2B—spinal cord—acquired immunodeficiency syndrome	0.000914	0.0141	CbGeAlD
Haloperidol—H1F0—retina—acquired immunodeficiency syndrome	0.000862	0.0133	CbGeAlD
Haloperidol—HTR2A—nerve—acquired immunodeficiency syndrome	0.000801	0.0124	CbGeAlD
Haloperidol—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000774	0.012	CbGeAlD
Haloperidol—GRIN2B—nervous system—acquired immunodeficiency syndrome	0.00077	0.0119	CbGeAlD
Haloperidol—H1F0—skin of body—acquired immunodeficiency syndrome	0.000756	0.0117	CbGeAlD
Haloperidol—CBR1—lymphoid tissue—acquired immunodeficiency syndrome	0.000748	0.0115	CbGeAlD
Haloperidol—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000747	0.0115	CbGeAlD
Haloperidol—GRIN2B—central nervous system—acquired immunodeficiency syndrome	0.000741	0.0114	CbGeAlD
Haloperidol—CBR1—digestive system—acquired immunodeficiency syndrome	0.000738	0.0114	CbGeAlD
Haloperidol—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000735	0.0113	CbGeAlD
Haloperidol—CBR1—blood—acquired immunodeficiency syndrome	0.000704	0.0109	CbGeAlD
Haloperidol—DRD4—brain—acquired immunodeficiency syndrome	0.000702	0.0108	CbGeAlD
Haloperidol—HTR2A—endothelium—acquired immunodeficiency syndrome	0.000682	0.0105	CbGeAlD
Haloperidol—CBR1—bone marrow—acquired immunodeficiency syndrome	0.000681	0.0105	CbGeAlD
Haloperidol—CBR1—spinal cord—acquired immunodeficiency syndrome	0.000678	0.0105	CbGeAlD
Haloperidol—CBR1—vagina—acquired immunodeficiency syndrome	0.000652	0.0101	CbGeAlD
Haloperidol—DRD3—nervous system—acquired immunodeficiency syndrome	0.000645	0.00996	CbGeAlD
Haloperidol—DRD3—central nervous system—acquired immunodeficiency syndrome	0.000621	0.00959	CbGeAlD
Haloperidol—CBR1—lung—acquired immunodeficiency syndrome	0.000617	0.00952	CbGeAlD
Haloperidol—H1F0—lymphoid tissue—acquired immunodeficiency syndrome	0.000613	0.00946	CbGeAlD
Haloperidol—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.000605	0.00935	CbGeAlD
Haloperidol—H1F0—digestive system—acquired immunodeficiency syndrome	0.000605	0.00934	CbGeAlD
Haloperidol—GRIN2B—brain—acquired immunodeficiency syndrome	0.000589	0.00909	CbGeAlD
Haloperidol—H1F0—blood—acquired immunodeficiency syndrome	0.000576	0.0089	CbGeAlD
Haloperidol—CBR1—nervous system—acquired immunodeficiency syndrome	0.000571	0.00882	CbGeAlD
Haloperidol—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000561	0.00865	CbGeAlD
Haloperidol—H1F0—bone marrow—acquired immunodeficiency syndrome	0.000558	0.00861	CbGeAlD
Haloperidol—H1F0—spinal cord—acquired immunodeficiency syndrome	0.000555	0.00857	CbGeAlD
Haloperidol—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000552	0.00852	CbGeAlD
Haloperidol—CBR1—central nervous system—acquired immunodeficiency syndrome	0.00055	0.00849	CbGeAlD
Haloperidol—HTR2B—skin of body—acquired immunodeficiency syndrome	0.000545	0.00842	CbGeAlD
Haloperidol—H1F0—vagina—acquired immunodeficiency syndrome	0.000534	0.00825	CbGeAlD
Haloperidol—H1F0—lung—acquired immunodeficiency syndrome	0.000505	0.0078	CbGeAlD
Haloperidol—DRD2—retina—acquired immunodeficiency syndrome	0.000503	0.00776	CbGeAlD
Haloperidol—DRD3—brain—acquired immunodeficiency syndrome	0.000493	0.00762	CbGeAlD
Haloperidol—H1F0—nervous system—acquired immunodeficiency syndrome	0.000468	0.00723	CbGeAlD
Haloperidol—DRD1—nervous system—acquired immunodeficiency syndrome	0.000462	0.00713	CbGeAlD
Haloperidol—H1F0—central nervous system—acquired immunodeficiency syndrome	0.000451	0.00696	CbGeAlD
Haloperidol—DRD1—central nervous system—acquired immunodeficiency syndrome	0.000445	0.00687	CbGeAlD
Haloperidol—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.000444	0.00686	CbGeAlD
Haloperidol—CBR1—brain—acquired immunodeficiency syndrome	0.000437	0.00674	CbGeAlD
Haloperidol—HTR2B—digestive system—acquired immunodeficiency syndrome	0.000436	0.00673	CbGeAlD
Haloperidol—CBR1—lymph node—acquired immunodeficiency syndrome	0.000422	0.00651	CbGeAlD
Haloperidol—SIGMAR1—blood—acquired immunodeficiency syndrome	0.000416	0.00643	CbGeAlD
Haloperidol—HTR2B—blood—acquired immunodeficiency syndrome	0.000415	0.00641	CbGeAlD
Haloperidol—SIGMAR1—bone marrow—acquired immunodeficiency syndrome	0.000403	0.00622	CbGeAlD
Haloperidol—SIGMAR1—spinal cord—acquired immunodeficiency syndrome	0.000401	0.00619	CbGeAlD
Haloperidol—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000397	0.00613	CbGeAlD
Haloperidol—SIGMAR1—vagina—acquired immunodeficiency syndrome	0.000386	0.00596	CbGeAlD
Haloperidol—HTR2B—vagina—acquired immunodeficiency syndrome	0.000385	0.00594	CbGeAlD
Haloperidol—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000374	0.00578	CbGeAlD
Haloperidol—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000367	0.00567	CbGeAlD
Haloperidol—SIGMAR1—lung—acquired immunodeficiency syndrome	0.000365	0.00563	CbGeAlD
Haloperidol—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000365	0.00563	CbGeAlD
Haloperidol—HTR2B—lung—acquired immunodeficiency syndrome	0.000364	0.00562	CbGeAlD
Haloperidol—HTR1D—nervous system—acquired immunodeficiency syndrome	0.000363	0.0056	CbGeAlD
Haloperidol—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.00036	0.00557	CbGeAlD
Haloperidol—H1F0—brain—acquired immunodeficiency syndrome	0.000358	0.00552	CbGeAlD
Haloperidol—DRD1—brain—acquired immunodeficiency syndrome	0.000353	0.00545	CbGeAlD
Haloperidol—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.000349	0.00539	CbGeAlD
Haloperidol—CYP2C19—blood—acquired immunodeficiency syndrome	0.000347	0.00536	CbGeAlD
Haloperidol—H1F0—lymph node—acquired immunodeficiency syndrome	0.000346	0.00534	CbGeAlD
Haloperidol—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000337	0.00521	CbGeAlD
Haloperidol—HTR2A—retina—acquired immunodeficiency syndrome	0.000332	0.00512	CbGeAlD
Haloperidol—KCNH2—blood—acquired immunodeficiency syndrome	0.000331	0.00512	CbGeAlD
Haloperidol—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.000325	0.00501	CbGeAlD
Haloperidol—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000322	0.00497	CbGeAlD
Haloperidol—KCNH2—bone marrow—acquired immunodeficiency syndrome	0.000321	0.00495	CbGeAlD
Haloperidol—KCNH2—spinal cord—acquired immunodeficiency syndrome	0.000319	0.00493	CbGeAlD
Haloperidol—KCNH2—vagina—acquired immunodeficiency syndrome	0.000307	0.00474	CbGeAlD
Haloperidol—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000298	0.0046	CbGeAlD
Haloperidol—DRD2—lung—acquired immunodeficiency syndrome	0.000295	0.00455	CbGeAlD
Haloperidol—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000294	0.00454	CbGeAlD
Haloperidol—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000287	0.00443	CbGeAlD
Haloperidol—HTR1B—brain—acquired immunodeficiency syndrome	0.000286	0.00442	CbGeAlD
Haloperidol—CYP1A2—blood—acquired immunodeficiency syndrome	0.000284	0.00438	CbGeAlD
Haloperidol—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000283	0.00436	CbGeAlD
Haloperidol—CYP1A1—blood—acquired immunodeficiency syndrome	0.00028	0.00432	CbGeAlD
Haloperidol—HRH1—digestive system—acquired immunodeficiency syndrome	0.000279	0.0043	CbGeAlD
Haloperidol—HTR1D—brain—acquired immunodeficiency syndrome	0.000277	0.00428	CbGeAlD
Haloperidol—CYP3A5—blood—acquired immunodeficiency syndrome	0.000274	0.00422	CbGeAlD
Haloperidol—DRD2—nervous system—acquired immunodeficiency syndrome	0.000273	0.00422	CbGeAlD
Haloperidol—CYP2C9—blood—acquired immunodeficiency syndrome	0.000269	0.00416	CbGeAlD
Haloperidol—KCNH2—nervous system—acquired immunodeficiency syndrome	0.000269	0.00415	CbGeAlD
Haloperidol—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000263	0.00406	CbGeAlD
Haloperidol—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000259	0.00401	CbGeAlD
Haloperidol—KCNH2—central nervous system—acquired immunodeficiency syndrome	0.000259	0.004	CbGeAlD
Haloperidol—SIGMAR1—brain—acquired immunodeficiency syndrome	0.000258	0.00399	CbGeAlD
Haloperidol—HTR2B—brain—acquired immunodeficiency syndrome	0.000258	0.00398	CbGeAlD
Haloperidol—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000254	0.00392	CbGeAlD
Haloperidol—SIGMAR1—lymph node—acquired immunodeficiency syndrome	0.00025	0.00385	CbGeAlD
Haloperidol—HTR2B—lymph node—acquired immunodeficiency syndrome	0.000249	0.00385	CbGeAlD
Haloperidol—CYP1A2—lung—acquired immunodeficiency syndrome	0.000249	0.00384	CbGeAlD
Haloperidol—HRH1—vagina—acquired immunodeficiency syndrome	0.000246	0.0038	CbGeAlD
Haloperidol—CYP1A1—lung—acquired immunodeficiency syndrome	0.000245	0.00379	CbGeAlD
Haloperidol—CYP3A5—lung—acquired immunodeficiency syndrome	0.00024	0.0037	CbGeAlD
Haloperidol—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000233	0.00359	CbGeAlD
Haloperidol—HRH1—lung—acquired immunodeficiency syndrome	0.000233	0.00359	CbGeAlD
Haloperidol—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000227	0.00351	CbGeAlD
Haloperidol—HTR2A—blood—acquired immunodeficiency syndrome	0.000222	0.00342	CbGeAlD
Haloperidol—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000219	0.00338	CbGeAlD
Haloperidol—ABCB1—retina—acquired immunodeficiency syndrome	0.000217	0.00335	CbGeAlD
Haloperidol—HRH1—nervous system—acquired immunodeficiency syndrome	0.000216	0.00333	CbGeAlD
Haloperidol—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000216	0.00333	CbGeAlD
Haloperidol—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000214	0.0033	CbGeAlD
Haloperidol—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000212	0.00327	CbGeAlD
Haloperidol—DRD2—brain—acquired immunodeficiency syndrome	0.000209	0.00322	CbGeAlD
Haloperidol—HRH1—central nervous system—acquired immunodeficiency syndrome	0.000208	0.0032	CbGeAlD
Haloperidol—HTR2A—vagina—acquired immunodeficiency syndrome	0.000206	0.00317	CbGeAlD
Haloperidol—KCNH2—brain—acquired immunodeficiency syndrome	0.000206	0.00317	CbGeAlD
Haloperidol—CYP3A4—blood—acquired immunodeficiency syndrome	0.000205	0.00317	CbGeAlD
Haloperidol—CYP2D6—blood—acquired immunodeficiency syndrome	0.000202	0.00312	CbGeAlD
Haloperidol—KCNH2—lymph node—acquired immunodeficiency syndrome	0.000199	0.00307	CbGeAlD
Haloperidol—HTR2A—lung—acquired immunodeficiency syndrome	0.000194	0.003	CbGeAlD
Haloperidol—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000194	0.00112	CcSEcCtD
Haloperidol—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000194	0.00111	CcSEcCtD
Haloperidol—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000193	0.00111	CcSEcCtD
Haloperidol—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000193	0.00111	CcSEcCtD
Haloperidol—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000193	0.00111	CcSEcCtD
Haloperidol—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000193	0.00111	CcSEcCtD
Haloperidol—Anorexia—Indinavir—acquired immunodeficiency syndrome	0.000192	0.00111	CcSEcCtD
Haloperidol—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000192	0.00111	CcSEcCtD
Haloperidol—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000191	0.0011	CcSEcCtD
Haloperidol—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000191	0.0011	CcSEcCtD
Haloperidol—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000191	0.0011	CcSEcCtD
Haloperidol—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00019	0.0011	CcSEcCtD
Haloperidol—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.00019	0.00109	CcSEcCtD
Haloperidol—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.00109	CcSEcCtD
Haloperidol—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.00019	0.00109	CcSEcCtD
Haloperidol—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000189	0.00108	CcSEcCtD
Haloperidol—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000187	0.00108	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000187	0.00108	CcSEcCtD
Haloperidol—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000187	0.00108	CcSEcCtD
Haloperidol—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000187	0.00107	CcSEcCtD
Haloperidol—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000186	0.00107	CcSEcCtD
Haloperidol—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000186	0.00107	CcSEcCtD
Haloperidol—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000186	0.00107	CcSEcCtD
Haloperidol—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000186	0.00107	CcSEcCtD
Haloperidol—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000185	0.00107	CcSEcCtD
Haloperidol—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000185	0.00106	CcSEcCtD
Haloperidol—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.000185	0.00106	CcSEcCtD
Haloperidol—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000184	0.00106	CcSEcCtD
Haloperidol—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000184	0.00106	CcSEcCtD
Haloperidol—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000184	0.00106	CcSEcCtD
Haloperidol—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000184	0.00106	CcSEcCtD
Haloperidol—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000184	0.00106	CcSEcCtD
Haloperidol—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000183	0.00105	CcSEcCtD
Haloperidol—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000183	0.00105	CcSEcCtD
Haloperidol—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000183	0.00105	CcSEcCtD
Haloperidol—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000182	0.00105	CcSEcCtD
Haloperidol—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000182	0.00105	CcSEcCtD
Haloperidol—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000182	0.00105	CcSEcCtD
Haloperidol—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000182	0.00104	CcSEcCtD
Haloperidol—Rash—Didanosine—acquired immunodeficiency syndrome	0.000181	0.00104	CcSEcCtD
Haloperidol—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000181	0.00104	CcSEcCtD
Haloperidol—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000181	0.00104	CcSEcCtD
Haloperidol—HTR2A—nervous system—acquired immunodeficiency syndrome	0.00018	0.00278	CbGeAlD
Haloperidol—Headache—Didanosine—acquired immunodeficiency syndrome	0.00018	0.00104	CcSEcCtD
Haloperidol—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00018	0.00103	CcSEcCtD
Haloperidol—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000179	0.00103	CcSEcCtD
Haloperidol—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000179	0.00103	CcSEcCtD
Haloperidol—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000179	0.00103	CcSEcCtD
Haloperidol—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000179	0.00103	CcSEcCtD
Haloperidol—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000179	0.00103	CcSEcCtD
Haloperidol—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000178	0.00103	CcSEcCtD
Haloperidol—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000178	0.00102	CcSEcCtD
Haloperidol—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000178	0.00102	CcSEcCtD
Haloperidol—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000178	0.00102	CcSEcCtD
Haloperidol—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000178	0.00102	CcSEcCtD
Haloperidol—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000177	0.00102	CcSEcCtD
Haloperidol—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000177	0.00102	CcSEcCtD
Haloperidol—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000177	0.00102	CcSEcCtD
Haloperidol—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000177	0.00102	CcSEcCtD
Haloperidol—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000176	0.00101	CcSEcCtD
Haloperidol—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000175	0.00101	CcSEcCtD
Haloperidol—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000175	0.00101	CcSEcCtD
Haloperidol—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000175	0.00101	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000175	0.001	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000174	0.001	CcSEcCtD
Haloperidol—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000174	0.001	CcSEcCtD
Haloperidol—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000174	0.001	CcSEcCtD
Haloperidol—CYP1A1—brain—acquired immunodeficiency syndrome	0.000174	0.00268	CbGeAlD
Haloperidol—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000173	0.00268	CbGeAlD
Haloperidol—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000172	0.000992	CcSEcCtD
Haloperidol—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000172	0.000991	CcSEcCtD
Haloperidol—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000172	0.000991	CcSEcCtD
Haloperidol—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000172	0.000991	CcSEcCtD
Haloperidol—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000172	0.00099	CcSEcCtD
Haloperidol—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000172	0.000988	CcSEcCtD
Haloperidol—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000171	0.000986	CcSEcCtD
Haloperidol—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000171	0.000985	CcSEcCtD
Haloperidol—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000171	0.000982	CcSEcCtD
Haloperidol—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000171	0.000982	CcSEcCtD
Haloperidol—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.00017	0.00098	CcSEcCtD
Haloperidol—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00017	0.00098	CcSEcCtD
Haloperidol—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00017	0.000978	CcSEcCtD
Haloperidol—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.00017	0.000977	CcSEcCtD
Haloperidol—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.00017	0.000977	CcSEcCtD
Haloperidol—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000169	0.000975	CcSEcCtD
Haloperidol—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000169	0.00097	CcSEcCtD
Haloperidol—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000169	0.00097	CcSEcCtD
Haloperidol—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000168	0.000967	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000168	0.000967	CcSEcCtD
Haloperidol—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000168	0.00259	CbGeAlD
Haloperidol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000168	0.000965	CcSEcCtD
Haloperidol—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000167	0.00257	CbGeAlD
Haloperidol—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000166	0.000956	CcSEcCtD
Haloperidol—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000166	0.000953	CcSEcCtD
Haloperidol—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000166	0.000952	CcSEcCtD
Haloperidol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000166	0.000952	CcSEcCtD
Haloperidol—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000165	0.000951	CcSEcCtD
Haloperidol—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000165	0.00095	CcSEcCtD
Haloperidol—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000165	0.000949	CcSEcCtD
Haloperidol—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000165	0.000949	CcSEcCtD
Haloperidol—HRH1—brain—acquired immunodeficiency syndrome	0.000165	0.00254	CbGeAlD
Haloperidol—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000165	0.000947	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000165	0.000946	CcSEcCtD
Haloperidol—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000164	0.000945	CcSEcCtD
Haloperidol—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000164	0.000945	CcSEcCtD
Haloperidol—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000164	0.00253	CbGeAlD
Haloperidol—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000164	0.000942	CcSEcCtD
Haloperidol—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000164	0.000941	CcSEcCtD
Haloperidol—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000163	0.000938	CcSEcCtD
Haloperidol—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000163	0.000937	CcSEcCtD
Haloperidol—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000163	0.000937	CcSEcCtD
Haloperidol—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000163	0.000936	CcSEcCtD
Haloperidol—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000163	0.000935	CcSEcCtD
Haloperidol—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000163	0.000935	CcSEcCtD
Haloperidol—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000162	0.000934	CcSEcCtD
Haloperidol—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000162	0.000932	CcSEcCtD
Haloperidol—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000162	0.000931	CcSEcCtD
Haloperidol—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000161	0.000926	CcSEcCtD
Haloperidol—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000161	0.000925	CcSEcCtD
Haloperidol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000161	0.000923	CcSEcCtD
Haloperidol—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.00016	0.00248	CbGeAlD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.00016	0.000923	CcSEcCtD
Haloperidol—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.00016	0.000922	CcSEcCtD
Haloperidol—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000159	0.000917	CcSEcCtD
Haloperidol—HRH1—lymph node—acquired immunodeficiency syndrome	0.000159	0.00246	CbGeAlD
Haloperidol—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000159	0.000916	CcSEcCtD
Haloperidol—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000159	0.000915	CcSEcCtD
Haloperidol—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000159	0.000914	CcSEcCtD
Haloperidol—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000159	0.000913	CcSEcCtD
Haloperidol—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000159	0.000912	CcSEcCtD
Haloperidol—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000158	0.000909	CcSEcCtD
Haloperidol—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000158	0.00244	CbGeAlD
Haloperidol—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000158	0.000908	CcSEcCtD
Haloperidol—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000158	0.000907	CcSEcCtD
Haloperidol—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000158	0.000907	CcSEcCtD
Haloperidol—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000158	0.000906	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000157	0.000906	CcSEcCtD
Haloperidol—Rash—Stavudine—acquired immunodeficiency syndrome	0.000157	0.000905	CcSEcCtD
Haloperidol—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000157	0.000904	CcSEcCtD
Haloperidol—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000157	0.000903	CcSEcCtD
Haloperidol—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000157	0.000902	CcSEcCtD
Haloperidol—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000157	0.000902	CcSEcCtD
Haloperidol—Headache—Stavudine—acquired immunodeficiency syndrome	0.000156	0.000899	CcSEcCtD
Haloperidol—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000156	0.000899	CcSEcCtD
Haloperidol—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000156	0.000898	CcSEcCtD
Haloperidol—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000156	0.000897	CcSEcCtD
Haloperidol—Rash—Abacavir—acquired immunodeficiency syndrome	0.000155	0.000892	CcSEcCtD
Haloperidol—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000155	0.000891	CcSEcCtD
Haloperidol—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000155	0.000891	CcSEcCtD
Haloperidol—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000155	0.000891	CcSEcCtD
Haloperidol—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000155	0.00089	CcSEcCtD
Haloperidol—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000154	0.00238	CbGeAlD
Haloperidol—Headache—Abacavir—acquired immunodeficiency syndrome	0.000154	0.000886	CcSEcCtD
Haloperidol—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000154	0.000883	CcSEcCtD
Haloperidol—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000153	0.000883	CcSEcCtD
Haloperidol—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000153	0.00236	CbGeAlD
Haloperidol—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000153	0.000877	CcSEcCtD
Haloperidol—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000152	0.000873	CcSEcCtD
Haloperidol—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000152	0.000872	CcSEcCtD
Haloperidol—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000152	0.000872	CcSEcCtD
Haloperidol—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000151	0.000871	CcSEcCtD
Haloperidol—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000151	0.000867	CcSEcCtD
Haloperidol—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.00015	0.000865	CcSEcCtD
Haloperidol—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.00015	0.000865	CcSEcCtD
Haloperidol—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00015	0.000864	CcSEcCtD
Haloperidol—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.00015	0.000862	CcSEcCtD
Haloperidol—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.00015	0.000861	CcSEcCtD
Haloperidol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000149	0.000855	CcSEcCtD
Haloperidol—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000149	0.000855	CcSEcCtD
Haloperidol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000148	0.000854	CcSEcCtD
Haloperidol—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000148	0.000854	CcSEcCtD
Haloperidol—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000148	0.000853	CcSEcCtD
Haloperidol—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000148	0.000849	CcSEcCtD
Haloperidol—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000147	0.000844	CcSEcCtD
Haloperidol—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000147	0.000843	CcSEcCtD
Haloperidol—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000146	0.00084	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000146	0.000837	CcSEcCtD
Haloperidol—ABCB1—blood—acquired immunodeficiency syndrome	0.000145	0.00224	CbGeAlD
Haloperidol—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000145	0.000833	CcSEcCtD
Haloperidol—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000145	0.000832	CcSEcCtD
Haloperidol—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000145	0.000832	CcSEcCtD
Haloperidol—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000144	0.00083	CcSEcCtD
Haloperidol—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000144	0.000829	CcSEcCtD
Haloperidol—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000144	0.000829	CcSEcCtD
Haloperidol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000143	0.000825	CcSEcCtD
Haloperidol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000143	0.000822	CcSEcCtD
Haloperidol—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000143	0.000821	CcSEcCtD
Haloperidol—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.000812	CcSEcCtD
Haloperidol—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000141	0.00217	CbGeAlD
Haloperidol—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.00014	0.000808	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.00014	0.000806	CcSEcCtD
Haloperidol—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.00014	0.00216	CbGeAlD
Haloperidol—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.000806	CcSEcCtD
Haloperidol—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000139	0.000799	CcSEcCtD
Haloperidol—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000139	0.000798	CcSEcCtD
Haloperidol—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000138	0.000794	CcSEcCtD
Haloperidol—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000138	0.000794	CcSEcCtD
Haloperidol—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000138	0.000793	CcSEcCtD
Haloperidol—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000138	0.000792	CcSEcCtD
Haloperidol—HTR2A—brain—acquired immunodeficiency syndrome	0.000138	0.00213	CbGeAlD
Haloperidol—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000137	0.000787	CcSEcCtD
Haloperidol—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000137	0.000786	CcSEcCtD
Haloperidol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000136	0.000784	CcSEcCtD
Haloperidol—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000136	0.000782	CcSEcCtD
Haloperidol—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000135	0.000776	CcSEcCtD
Haloperidol—ABCB1—vagina—acquired immunodeficiency syndrome	0.000135	0.00208	CbGeAlD
Haloperidol—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000774	CcSEcCtD
Haloperidol—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000134	0.000773	CcSEcCtD
Haloperidol—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000134	0.000771	CcSEcCtD
Haloperidol—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000134	0.000769	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.000769	CcSEcCtD
Haloperidol—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000133	0.000767	CcSEcCtD
Haloperidol—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000133	0.000767	CcSEcCtD
Haloperidol—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000132	0.000762	CcSEcCtD
Haloperidol—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.00013	0.00075	CcSEcCtD
Haloperidol—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000129	0.000742	CcSEcCtD
Haloperidol—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000129	0.000742	CcSEcCtD
Haloperidol—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000129	0.000741	CcSEcCtD
Haloperidol—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000128	0.000738	CcSEcCtD
Haloperidol—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000128	0.000738	CcSEcCtD
Haloperidol—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000128	0.000734	CcSEcCtD
Haloperidol—ABCB1—lung—acquired immunodeficiency syndrome	0.000127	0.00197	CbGeAlD
Haloperidol—Rash—Indinavir—acquired immunodeficiency syndrome	0.000127	0.000732	CcSEcCtD
Haloperidol—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000127	0.000731	CcSEcCtD
Haloperidol—Headache—Indinavir—acquired immunodeficiency syndrome	0.000126	0.000727	CcSEcCtD
Haloperidol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000126	0.000725	CcSEcCtD
Haloperidol—CYP2D6—brain—acquired immunodeficiency syndrome	0.000125	0.00194	CbGeAlD
Haloperidol—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000125	0.000718	CcSEcCtD
Haloperidol—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000124	0.000715	CcSEcCtD
Haloperidol—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000123	0.000708	CcSEcCtD
Haloperidol—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000122	0.000704	CcSEcCtD
Haloperidol—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000121	0.000697	CcSEcCtD
Haloperidol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000121	0.000694	CcSEcCtD
Haloperidol—Rash—Efavirenz—acquired immunodeficiency syndrome	0.00012	0.000691	CcSEcCtD
Haloperidol—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.00012	0.000691	CcSEcCtD
Haloperidol—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00012	0.000689	CcSEcCtD
Haloperidol—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00012	0.000688	CcSEcCtD
Haloperidol—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000119	0.000687	CcSEcCtD
Haloperidol—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.000686	CcSEcCtD
Haloperidol—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000118	0.00182	CbGeAlD
Haloperidol—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000116	0.000667	CcSEcCtD
Haloperidol—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000115	0.000664	CcSEcCtD
Haloperidol—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000115	0.000661	CcSEcCtD
Haloperidol—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000115	0.000661	CcSEcCtD
Haloperidol—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.00066	CcSEcCtD
Haloperidol—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000114	0.000657	CcSEcCtD
Haloperidol—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000114	0.000656	CcSEcCtD
Haloperidol—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000114	0.00175	CbGeAlD
Haloperidol—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000113	0.000651	CcSEcCtD
Haloperidol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000641	CcSEcCtD
Haloperidol—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000639	CcSEcCtD
Haloperidol—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.00063	CcSEcCtD
Haloperidol—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000108	0.000623	CcSEcCtD
Haloperidol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000617	CcSEcCtD
Haloperidol—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000107	0.000617	CcSEcCtD
Haloperidol—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000612	CcSEcCtD
Haloperidol—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000611	CcSEcCtD
Haloperidol—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000106	0.000609	CcSEcCtD
Haloperidol—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000608	CcSEcCtD
Haloperidol—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000594	CcSEcCtD
Haloperidol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000589	CcSEcCtD
Haloperidol—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000589	CcSEcCtD
Haloperidol—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000588	CcSEcCtD
Haloperidol—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000585	CcSEcCtD
Haloperidol—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.0001	0.000576	CcSEcCtD
Haloperidol—Vomiting—Lamivudine—acquired immunodeficiency syndrome	9.84e-05	0.000566	CcSEcCtD
Haloperidol—Rash—Lamivudine—acquired immunodeficiency syndrome	9.76e-05	0.000562	CcSEcCtD
Haloperidol—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	9.75e-05	0.000561	CcSEcCtD
Haloperidol—Headache—Lamivudine—acquired immunodeficiency syndrome	9.7e-05	0.000558	CcSEcCtD
Haloperidol—Nausea—Saquinavir—acquired immunodeficiency syndrome	9.64e-05	0.000555	CcSEcCtD
Haloperidol—Nausea—Lamivudine—acquired immunodeficiency syndrome	9.2e-05	0.000529	CcSEcCtD
Haloperidol—ABCB1—brain—acquired immunodeficiency syndrome	9.02e-05	0.00139	CbGeAlD
Haloperidol—ABCB1—lymph node—acquired immunodeficiency syndrome	8.72e-05	0.00135	CbGeAlD
Haloperidol—HTR2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.22e-05	0.00084	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.19e-05	0.000828	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.19e-05	0.000826	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.19e-05	0.000826	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.16e-05	0.000817	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	2.15e-05	0.000812	CbGpPWpGaD
Haloperidol—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	2.14e-05	0.000808	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.1e-05	0.000792	CbGpPWpGaD
Haloperidol—DRD2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.08e-05	0.000785	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.07e-05	0.000782	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.06e-05	0.000779	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.06e-05	0.000779	CbGpPWpGaD
Haloperidol—HTR2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.05e-05	0.000773	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.04e-05	0.000771	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.03e-05	0.000769	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.03e-05	0.000769	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.03e-05	0.000767	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.99e-05	0.000752	CbGpPWpGaD
Haloperidol—HTR2A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	1.97e-05	0.000746	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.96e-05	0.000741	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	1.95e-05	0.000738	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.95e-05	0.000737	CbGpPWpGaD
Haloperidol—DRD4—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.94e-05	0.000735	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.92e-05	0.000726	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.92e-05	0.000725	CbGpPWpGaD
Haloperidol—GRIN2B—Axon guidance—IL6—acquired immunodeficiency syndrome	1.92e-05	0.000724	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.91e-05	0.00072	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.89e-05	0.000714	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.83e-05	0.000692	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.83e-05	0.000692	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.82e-05	0.000689	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.81e-05	0.000683	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.8e-05	0.000682	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.8e-05	0.000681	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.8e-05	0.000679	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.8e-05	0.000679	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.79e-05	0.000678	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.79e-05	0.000678	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.79e-05	0.000676	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.78e-05	0.000673	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	1.78e-05	0.000673	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.77e-05	0.000669	CbGpPWpGaD
Haloperidol—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.76e-05	0.000664	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.76e-05	0.000664	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.75e-05	0.000661	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.75e-05	0.000661	CbGpPWpGaD
Haloperidol—DRD1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.75e-05	0.000661	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.74e-05	0.000659	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.74e-05	0.000658	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.73e-05	0.000653	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.73e-05	0.000653	CbGpPWpGaD
Haloperidol—DRD3—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.73e-05	0.000652	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.72e-05	0.000651	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.72e-05	0.000651	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.72e-05	0.000649	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.72e-05	0.000649	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.72e-05	0.000648	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.71e-05	0.000648	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.71e-05	0.000648	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.7e-05	0.000644	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.7e-05	0.000643	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.7e-05	0.00064	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.69e-05	0.000637	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.69e-05	0.000637	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.68e-05	0.000636	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.68e-05	0.000636	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.68e-05	0.000634	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.66e-05	0.000628	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	1.66e-05	0.000627	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.66e-05	0.000626	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.65e-05	0.000624	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.65e-05	0.000623	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.64e-05	0.000619	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.63e-05	0.000615	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.63e-05	0.000615	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.63e-05	0.000615	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.63e-05	0.000614	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.62e-05	0.000612	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.62e-05	0.000611	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.6e-05	0.000603	CbGpPWpGaD
Haloperidol—HTR2A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.59e-05	0.000602	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.59e-05	0.000601	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.58e-05	0.000598	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.57e-05	0.000593	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.57e-05	0.000593	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.56e-05	0.000589	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.56e-05	0.000588	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.56e-05	0.000588	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.56e-05	0.000588	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.55e-05	0.000587	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.55e-05	0.000585	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.55e-05	0.000584	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.54e-05	0.00058	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.53e-05	0.000579	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.53e-05	0.000579	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.53e-05	0.000577	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.53e-05	0.000577	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.53e-05	0.000577	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.52e-05	0.000576	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.52e-05	0.000575	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.52e-05	0.000574	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.51e-05	0.000572	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.5e-05	0.000566	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.49e-05	0.000564	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.46e-05	0.000552	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.44e-05	0.000544	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.43e-05	0.000541	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.41e-05	0.000534	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.41e-05	0.000534	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.4e-05	0.00053	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.4e-05	0.00053	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.39e-05	0.000527	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.38e-05	0.000519	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.38e-05	0.000519	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.37e-05	0.000519	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.37e-05	0.000517	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.35e-05	0.000511	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.35e-05	0.000511	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.32e-05	0.000499	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.3e-05	0.000493	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.3e-05	0.000489	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.29e-05	0.000489	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.29e-05	0.000488	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.29e-05	0.000488	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.28e-05	0.000485	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.28e-05	0.000485	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.28e-05	0.000484	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.28e-05	0.000483	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.26e-05	0.000478	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.26e-05	0.000476	CbGpPWpGaD
Haloperidol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.23e-05	0.000465	CbGpPWpGaD
Haloperidol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.23e-05	0.000464	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.22e-05	0.00046	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.22e-05	0.00046	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.2e-05	0.000454	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.2e-05	0.000454	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.18e-05	0.000447	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.18e-05	0.000444	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.17e-05	0.000444	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.17e-05	0.000441	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.17e-05	0.00044	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.16e-05	0.000439	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.16e-05	0.000437	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.15e-05	0.000436	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.15e-05	0.000434	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.15e-05	0.000433	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.08e-05	0.000409	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.07e-05	0.000404	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.07e-05	0.000403	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.06e-05	0.000402	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.06e-05	0.000401	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.06e-05	0.000399	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.05e-05	0.000398	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.05e-05	0.000397	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.05e-05	0.000396	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.05e-05	0.000395	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.04e-05	0.000392	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.03e-05	0.000389	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.03e-05	0.000389	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.02e-05	0.000383	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.01e-05	0.000383	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.99e-06	0.000377	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	9.99e-06	0.000377	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.83e-06	0.000371	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.78e-06	0.00037	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.68e-06	0.000366	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.63e-06	0.000364	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.63e-06	0.000364	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.61e-06	0.000363	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.54e-06	0.00036	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.43e-06	0.000356	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.42e-06	0.000356	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.35e-06	0.000353	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.28e-06	0.00035	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.27e-06	0.00035	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.22e-06	0.000348	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.2e-06	0.000347	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.2e-06	0.000347	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.15e-06	0.000345	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.13e-06	0.000345	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.07e-06	0.000343	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.05e-06	0.000342	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.05e-06	0.000342	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.03e-06	0.000341	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.03e-06	0.000341	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.01e-06	0.00034	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.99e-06	0.00034	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.87e-06	0.000335	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.85e-06	0.000334	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.66e-06	0.000327	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.35e-06	0.000315	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.24e-06	0.000311	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.17e-06	0.000308	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.06e-06	0.000304	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.65e-06	0.000289	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—ALB—acquired immunodeficiency syndrome	7.25e-06	0.000274	CbGpPWpGaD
Haloperidol—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	7.1e-06	0.000268	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7e-06	0.000264	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.98e-06	0.000263	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.89e-06	0.00026	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.89e-06	0.00026	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.87e-06	0.000259	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.79e-06	0.000256	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.78e-06	0.000256	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.77e-06	0.000256	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.68e-06	0.000252	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.67e-06	0.000252	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.3e-06	0.000238	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.2e-06	0.000234	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.19e-06	0.000234	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.17e-06	0.000233	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	6.1e-06	0.00023	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.07e-06	0.000229	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.05e-06	0.000229	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.96e-06	0.000225	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.56e-06	0.00021	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.53e-06	0.000209	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.45e-06	0.000206	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.42e-06	0.000205	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.36e-06	0.000202	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.33e-06	0.000201	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.12e-06	0.000193	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.09e-06	0.000192	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.82e-06	0.000182	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.8e-06	0.000181	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.76e-06	0.00018	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.74e-06	0.000179	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	4.41e-06	0.000166	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	4.16e-06	0.000157	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.64e-06	0.000138	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.62e-06	0.000137	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.58e-06	0.000135	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.58e-06	0.000135	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.57e-06	0.000135	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.56e-06	0.000134	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	3.41e-06	0.000129	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	3.33e-06	0.000126	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.27e-06	0.000123	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.2e-06	0.000121	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.15e-06	0.000119	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	3.13e-06	0.000118	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	3.11e-06	0.000117	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.01e-06	0.000114	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.84e-06	0.000107	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.8e-06	0.000106	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	2.65e-06	0.0001	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.14e-06	8.09e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.11e-06	7.96e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.1e-06	7.94e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.05e-06	7.74e-05	CbGpPWpGaD
